185 results on '"Balduzzi, S"'
Search Results
2. Predictive Role Of Body Composition Parameters In Operable Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
3. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer
4. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
5. LBA31 Neoadjuvant nivolumab plus relatlimab (anti-LAG3) in locally advanced MMR-deficient colon cancers: The NICHE-3 study
6. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
7. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer:study protocol of the INDIBLADE trial
8. Induction therapy with ipilimumab and nivolumab followed by consolidative chemoradiation as organ-sparing treatment in urothelial bladder cancer: study protocol of the INDIBLADE trial
9. The impact of shift work on the psychological and physical health of nurses in a general hospital: a comparison between rotating night shifts and day shifts
10. 1780TiP A phase II clinical study to assess efficacy of induction ipilimumab/nivolumab to spare the bladder in urothelial bladder cancer (INDI-BLADE)
11. 1219P Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction (G/GEJ) adenocarcinoma: The PANDA study
12. 503O Neoadjuvant nivolumab (nivo) plus relatlimab (rela) in MMR-deficient colon cancer: Results of the NICHE-3 study
13. 239MO TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
14. 236MO Pathologic complete response and survival after neoadjuvant chemotherapy in stage I TNBC: A registry-based study
15. LBA24 Neoadjuvant immunotherapy in locally advanced MMR-deficient colon cancer: 3-year disease-free survival from NICHE-2
16. LBA20 First-line carboplatin-cyclophosphamide (CC) versus paclitaxel (P) with or without atezolizumab (atezo) for metastatic triple negative breast cancer (mTNBC): Results from a multicenter, randomized phase IIb trial: The Triple-B study (BOOG 2013-01)
17. LBA14 Intensified alkylating chemotherapy with autologous stem cell rescue (IACT) or conventional chemotherapy followed by olaparib (CCT-O) in stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer (BC): Survival results of the randomized-controlled SUBITO trial
18. Correspondence on 'EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs'
19. AB0224 JAK-INHIBITORS ATTAIN A RAPID AND PERSISTENT EFFECTIVENESS ON SEVERAL PATIENT-REPORTED OUTCOMES IN LONG-STANDING RHEUMATOID ARTHRITIS
20. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
21. Correction to: Impact of smoking habit on adult-onset Still’s disease prognosis, findings from a multicentre observational study (Clinical Rheumatology, (2022), 41, 3, (641-647), 10.1007/s10067-021-05929-8)
22. OP0093 RETENTION RATE OF IL-1 INHIBITORS IN PATIENTS WITH SCHNITZLER’S SYNDROME
23. 41O Nine weeks vs 1-year adjuvant trastuzumab: Long term outcomes of the ShortHER randomised trial
24. Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA
25. Introduction and methods of the evidence-based guidelines for the diagnosis and management of autism spectrum disorder by the Italian National Institute of Health
26. Herbal supplements in pregnancy: unexpected results from a multicentre study
27. FRI0273 EFFECTIVENESS AND RETENTION RATE OF SECUKINUMAB FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS: REAL-LIFE DATA FROM THE ITALIAN LORHEN REGISTRY
28. AB0462 BEHCET’S DISEASE: CLINICAL FEATURES AND OFF-LABEL BIOLOGIC TREATMENT STRATEGIES
29. Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study
30. In early inflammatory polyarthritis more intensive management according to the 2010 ACR/EULAR criteria leads to higher rates of clinical remission: Comparison of two cohorts treated according to different treat to target protocols
31. Clinical differences in sarcoidosis patients with and without lymphoma: A single-centre retrospective cohort analysis
32. Validation of the American Joint Committee on Cancer new prognostic stage groups for HER2-positive breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the prospective ShortHER trial
33. Effectiveness of support groups to improve the quality of life of people with idiopathic pulmonary fibrosis a pre-post test pilot study
34. 3* Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
35. 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
36. AB0700 Is it feasible to withdraw immunosuppressive treatment in real-life patients with anca-associated vasculitis?
37. Abstract P1-13-02: Withdrawn
38. Indicators of Complex Care During the Consultation-Liaison Psychiatry Activity at the Transplant Center of the Policlinico Hospital, Modena
39. Estimate of false-positive breast cancer diagnoses from accuracy studies: A systematic review
40. TIPIZZAZIONE CLINICA DELLA SINDROME ANTISINTETASICA: CONFRONTO TRA PAZIENTI ANTI JO-1 POSITIVI E NEGATIVI
41. Final analysis of the phase III multicentric Italian study Short-HER: 9 weeks vs 1 year adjuvant trastuzumab for HER2+ early breast cancer
42. AB0589 The role of anca specificity in the clinical manifestations at disease onset: comparison between patients with granulomatosis with polyangiitis and microscopic polyangiitis
43. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients
44. Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial
45. Non-steroid agents for idiopathic pulmonary fibrosis
46. PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data
47. Safety and efficacy of T-DM1 in HER2 positive metastatic breast cancer patients: a real word experience
48. AB0569 Does The Age at Disease Onset Influence The Clinical Presentation and Long-Term Outcome of Anca-Associated Vasculitides? Results from A Single-Centre Cohort: Table 1.
49. 191PD_PR - 9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio
50. Short and long term effects of tibolone in postmenopausal women
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.